Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

The decision came in response to a February lawsuit from a compounding industry group against the FDA's decision that there ...

New weight loss drugs work by switching off your appetite but, says leading psychological therapist Jo Silver, turning off ...

A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...

New Delhi: Torrent Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

With age comes wisdom. But you know what else can come with age? Weight gain. Losing weight can also be harder as you grow ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final resolution.

Lee Rosebush, chairman of lead plaintiff Outsourcing Facilities Association, told Reuters that his organization had presented evidence of an ongoing semaglutide shortage that was obtained after ...